Literature DB >> 2965654

Effects of triflusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients.

J P De la Cruz1, J Pavia, J Garcia-Arnes, F Sanchez de la Cuesta.   

Abstract

A study was made on the inhibitory effect of triflusal (600 mg/d X 15) and acetylsalicylic acid (ASA, 400 mg/d X 15) on platelet aggregation in whole blood (WB) and platelet-rich plasma (PRP) induced by ADP (2.5 mumol/l), adrenaline (50 mumol/l), collagen (1 microgram/ml) and arachidonic acid (0.8 mmol/l), in 30 insulin-dependent diabetic patients without vascular complications. Determination was also made of the serum levels of thromboxane B2 (TxB2) and of the plasma levels of 6-keto-PGF1-alpha and of beta-thromboglobulin (B-TG). Both drugs exhibited higher inhibitory effects in WB than in PRP. In WB, a significant difference between triflusal and ASA was observed against ADP-induced aggregation (67% and 46% inhibition respectively, p less than 0.01). Both drugs strongly inhibit the formation of TxB2 in serum (85% and 99%, respectively). Triflusal does not significantly change the plasma levels of 6-keto-PGF1-alpha; ASA, by contrast, causes reduction of over 95% in those plasma levels. The plasma levels of B-TG were not modified by either of the drugs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965654     DOI: 10.1111/j.1600-0609.1988.tb00829.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  8 in total

Review 1.  Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation.

Authors:  David Murdoch; Greg L Plosker
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Triflusal : A Viewpoint by José P. De La Cruz.

Authors:  J P De La Cruz
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

3.  Protective effect of triflusal and its main metabolite HTB in an in vitro model of anoxia-reoxygenation in rat brain slices: comparison with acetylsalicylic and salicylic acids.

Authors:  J A González-Correa; M M Arrebola; I M Ureña; D Ruiz-Villafranca; J Muñoz-Marín; A Guerrero; F Sánchez de la Cuesta; J P De La Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-12-16       Impact factor: 3.000

4.  Antiplatelet effect of the anaesthetic drug propofol: influence of red blood cells and leucocytes.

Authors:  J P De La Cruz; M V Páez; J A Carmona; F S De La Cuesta
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 5.  Triflusal.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

6.  Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers.

Authors:  J P De La Cruz; M A Villalobos; P J García; J M Smith-Agreda; F Sánchez de la Cuesta
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

7.  Antioxidant and antiplatelet activities of flavonoid-rich fractions of three citrus fruits from Korea.

Authors:  Awraris Derbie Assefa; Eun Young Ko; So Hyun Moon; Young-Soo Keum
Journal:  3 Biotech       Date:  2016-04-19       Impact factor: 2.406

8.  Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial.

Authors:  Sanghoon Shin; Kwang-Joon Kim; In-Jeong Cho; Geu-Ru Hong; Yangsoo Jang; Namsik Chung; Young Min Rah; Hyuk-Jae Chang
Journal:  Yonsei Med J       Date:  2015-09       Impact factor: 2.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.